MCID: DRG002
MIFTS: 41

Drug-Induced Hepatitis

Categories: Endocrine diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Drug-Induced Hepatitis

MalaCards integrated aliases for Drug-Induced Hepatitis:

Name: Drug-Induced Hepatitis 38 12 15
Chemical and Drug Induced Liver Injury, Chronic 44
Hepatitis, Chronic, Drug-Induced 73
Drug-Induced Chronic Hepatitis 12
Hepatitis, Drug-Induced 73

Classifications:



External Ids:

Disease Ontology 12 DOID:2044
MeSH 44 D056487

Summaries for Drug-Induced Hepatitis

MalaCards based summary : Drug-Induced Hepatitis, also known as chemical and drug induced liver injury, chronic, is related to hepatitis and isoniazid toxicity. An important gene associated with Drug-Induced Hepatitis is NAT2 (N-Acetyltransferase 2), and among its related pathways/superpathways are Metabolism and Cytochrome P450 - arranged by substrate type. The drugs Acetylcysteine and Lamivudine have been mentioned in the context of this disorder. Affiliated tissues include Liver, liver and testes.

Wikipedia : 76 Hepatotoxicity (from hepatic toxicity) implies chemical-driven liver damage. Drug-induced liver injury... more...

Related Diseases for Drug-Induced Hepatitis

Diseases related to Drug-Induced Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Related Disease Score Top Affiliating Genes
1 hepatitis 10.7
2 isoniazid toxicity 10.2 CYP2E1 NAT2
3 colorectal cancer, childhood 10.2 GSTM1 NAT2
4 methemoglobinemia 10.1 CYP2E1 NAT2
5 hearing loss, noise-induced 10.1 GSTM1 GSTT1
6 isolated cleft lip 10.1 GSTM1 GSTT1
7 pulmonary tuberculosis 10.1
8 oral leukoplakia 10.1 GSTM1 GSTT1
9 leukoplakia 10.1 GSTM1 GSTT1
10 cardia cancer 10.1 GSTM1 GSTT1
11 halothane hepatitis 10.1 CYP2C9 CYP2E1
12 arteritic anterior ischemic optic neuropathy 10.1 GSTM1 GSTT1
13 ischemic optic neuropathy 10.1 GSTM1 GSTT1
14 senile cataract 10.1 GSTM1 GSTT1
15 diffuse gastric cancer 10.1 GSTM1 GSTT1
16 laryngeal disease 10.1 GSTM1 GSTT1
17 xeroderma pigmentosum, complementation group d 10.1 GSTM1 GSTT1
18 asbestosis 10.1 GSTM1 GSTT1
19 sulfonamide allergy 10.1 CYP2C9 CYP2D6
20 oligospermia 10.1 GSTM1 GSTT1
21 esophageal candidiasis 10.1 CYP2C19 CYP2C9
22 oral submucous fibrosis 10.1 GSTM1 GSTT1
23 antidepressant or antipsychotic toxicity or dose selection 10.1 CYP2C19 CYP2D6
24 clopidogrel resistance 10.0 CYP2C19 CYP2C9
25 varicocele 10.0 GSTM1 GSTT1
26 alcoholic liver cirrhosis 10.0 CYP2E1 GSTM1 NAT2
27 mutagen sensitivity 10.0 GSTM1 GSTT1 NAT2
28 sister chromatid exchange, frequency of 10.0 CYP2E1 GSTM1 GSTT1
29 toxic encephalopathy 10.0 GSTM1 GSTT1
30 bladder disease 10.0 GSTM1 GSTT1 NAT2
31 larynx cancer 10.0 GSTM1 GSTT1 NAT2
32 oral cancer 10.0 GSTM1 GSTT1
33 toxic oil syndrome 10.0 CYP2D6 GSTM1 NAT2
34 respiratory system cancer 10.0 CYP2E1 GSTM1
35 phenytoin toxicity 10.0 CYP2C19 CYP2C9 NAT2
36 basal cell carcinoma 9.9 CYP2D6 GSTM1 GSTT1
37 oral cavity cancer 9.9 CYP2E1 GSTM1 GSTT1 NAT2
38 hepatitis b 9.9
39 hepatitis a 9.9
40 meningitis 9.9
41 hepatitis d 9.8 CYP2C9 CYP2D6 IFNL3
42 substance dependence 9.8 CYP2D6 GSTM1
43 myeloma, multiple 9.7
44 hyperinsulinemic hypoglycemia, familial, 3 9.7
45 hyperinsulinemic hypoglycemia, familial, 5 9.7
46 hyperinsulinemic hypoglycemia, familial, 4 9.7
47 fatty liver disease, nonalcoholic 1 9.7
48 autoimmune hepatitis 9.7
49 hepatic veno-occlusive disease 9.7
50 porphyria 9.7

Graphical network of the top 20 diseases related to Drug-Induced Hepatitis:



Diseases related to Drug-Induced Hepatitis

Symptoms & Phenotypes for Drug-Induced Hepatitis

Drugs & Therapeutics for Drug-Induced Hepatitis

Drugs for Drug-Induced Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
2
Lamivudine Approved, Investigational Phase 3 134678-17-4 60825
3 Dolutegravir Approved Phase 3 1051375-16-6 54726191
4
Abacavir Approved, Investigational Phase 3 136470-78-5 65140 441300
5 Anti-Bacterial Agents Phase 2, Phase 3
6 Anti-Infective Agents Phase 2, Phase 3
7 Antitubercular Agents Phase 2, Phase 3
8 Antioxidants Phase 2, Phase 3
9 Expectorants Phase 2, Phase 3
10 N-monoacetylcystine Phase 2, Phase 3
11 Antidotes Phase 2, Phase 3
12 Antiviral Agents Phase 2, Phase 3
13 Free Radical Scavengers Phase 2, Phase 3
14 Liver Extracts Phase 2, Phase 3
15 Respiratory System Agents Phase 2, Phase 3
16 Protective Agents Phase 2, Phase 3
17 Integrase Inhibitors Phase 3
18
Rifampicin Approved 13292-46-1 5458213 5381226
19
Isoniazid Approved, Investigational 54-85-3 3767
20
Pyrazinamide Approved, Investigational 98-96-4 1046
21
Pomegranate Experimental, Investigational Not Applicable
22 interferons

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis Recruiting NCT02182167 Phase 2, Phase 3 IV N-acetylcysteine (NAC);Water
2 ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection Suspended NCT02075593 Phase 3 DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets
3 Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis Completed NCT00834353 ATT
4 Anti-tuberculosis (TB) Drug Levels and Hepatotoxicity Completed NCT00929786
5 The Beneficial Effects of Pomegranate on Hearing of Patients Without Hemodialysis Recruiting NCT03575390 Not Applicable
6 Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection Recruiting NCT03312647

Search NIH Clinical Center for Drug-Induced Hepatitis

Cochrane evidence based reviews: chemical and drug induced liver injury, chronic

Genetic Tests for Drug-Induced Hepatitis

Anatomical Context for Drug-Induced Hepatitis

MalaCards organs/tissues related to Drug-Induced Hepatitis:

41
Liver, Testes, T Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Drug-Induced Hepatitis:
# Tissue Anatomical CompartmentCell Relevance
1 Liver Liver Lobule Hepatocytes Affected by disease

Publications for Drug-Induced Hepatitis

Articles related to Drug-Induced Hepatitis:

(show top 50) (show all 94)
# Title Authors Year
1
Is drug-induced hepatitis related to the severity of tuberculous meningitis? ( 29438557 )
2018
2
Baseline HBV load increases the risk of anti-tuberculous drug-induced hepatitis flares in patients with tuberculosis. ( 28224437 )
2017
3
Compensatory variances of drug-induced hepatitis B virus YMDD mutations. ( 27588233 )
2016
4
Superoxide Dismutase Gene (SOD1, SOD2, and SOD3) Polymorphisms and Antituberculosis Drug-induced Hepatitis. ( 25553268 )
2015
5
Characteristics of Mononuclear Extracellular Traps in the Offspring of Female Rats with Drug-Induced Hepatitis. ( 26388577 )
2015
6
Troxis necrosis, a novel mechanism for drug-induced hepatitis secondary to immunomodulatory therapy. ( 26297838 )
2015
7
Analysis of IL-6, STAT3 and HSPA1L Gene Polymorphisms in Anti-Tuberculosis Drug-Induced Hepatitis in a Nested Case-Control Study. ( 25789467 )
2015
8
Recurrent Drug-Induced Hepatitis in Tuberculosis-Comparison of Two Drug Regimens. ( 26057141 )
2015
9
Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients. ( 25949974 )
2015
10
Epstein-Barr Virus Infection Mimicking Drug-Induced Hepatitis in a Critically ill Patient During Antituberculosis Therapy. ( 25368656 )
2014
11
Is antiviral drug-induced hepatitis B surface antigen loss durable? ( 25457852 )
2014
12
Risk factors for drug-induced hepatitis with first-line antituberculosis drugs in hospitalized patients of pulmonary tuberculosis. ( 24823543 )
2014
13
Risk factors for drug induced hepatitis with first-line antituberculosis drugs in hospitalized patients of pulmonary tuberculosis. ( 24625953 )
2014
14
Comments on 'Risk factors for drug induced hepatitis with first-line antituberculosis drugs in hospitalized patients of pulmonary tuberculosis'. ( 24823542 )
2014
15
Authors' reply to Comment on "No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance" [Dig. Liver Dis.2014;46:348-52]. ( 24890620 )
2014
16
Comment on "No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance" by Ubaldo Visco-Comandini et al. [Dig. Liver Dis. 2014;46:348-52]. ( 24815081 )
2014
17
Efficacy of herbal coded Hepcon on drug induced hepatitis in experimental animals through histopathological and biochemical analysis. ( 24035958 )
2013
18
No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance. ( 24387833 )
2013
19
A rare coexistence: drug induced hepatitis and meningitis in association with Ibuprofen. ( 23671551 )
2013
20
Hyperacute drug-induced hepatitis with intravenous amiodarone: case report and review of the literature. ( 24109195 )
2013
21
Cytochrome P450 2E1 gene polymorphisms/haplotypes and anti-tuberculosis drug-induced hepatitis in a Chinese cohort. ( 23460870 )
2013
22
Anti-tuberculosis drug-induced hepatitis in renal transplant patient with pulmonary and extra pulmonary tuberculosis. ( 23960791 )
2012
23
A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma. ( 22916049 )
2012
24
A rare cause of drug-induced hepatitis in an immunocompromised patient and the role of glutathione. ( 22993667 )
2012
25
Drug-induced hepatitis following use of octreotide for long-term treatment of congenital hyperinsulinism. ( 22850563 )
2012
26
TNF-I+ genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis. ( 22151084 )
2012
27
Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. ( 22012226 )
2011
28
A Case of Drug-Induced Hepatitis due to Lenalidomide. ( 21552449 )
2011
29
Zhixue capsule caused seven cases of drug induced hepatitis. ( 20698229 )
2010
30
Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases. ( 19535968 )
2010
31
Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review. ( 20338127 )
2010
32
NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. ( 20392357 )
2010
33
Remission of drug-induced hepatitis after switching from risperidone to paliperidone. ( 20194492 )
2010
34
Acute drug-induced hepatitis caused by albendazole. ( 18955802 )
2008
35
Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. ( 18830542 )
2008
36
Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests. ( 18330759 )
2008
37
Drug-induced hepatitis superimposed on the presence of anti-SLA antibody: a case report. ( 18226219 )
2008
38
Acute drug induced hepatitis due to erlotinib. ( 17228132 )
2007
39
Acute drug induced hepatitis secondary to a weight loss product purchased over the internet. ( 17597525 )
2007
40
Drug-induced hepatitis - morphological and ultrastructural aspects. ( 18060200 )
2007
41
Rescue therapy by portal infusion of autologous stem cells in a case of drug-induced hepatitis. ( 16875890 )
2007
42
Drug induced hepatitis with anti-tubercular chemotherapy: challenges and difficulties in treatment. ( 18604033 )
2007
43
Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. ( 16728538 )
2006
44
A case of acute drug-induced hepatitis. ( 16607204 )
2006
45
Role of CYP2E1 immunoglobulin G4 subclass antibodies and complement in pathogenesis of idiosyncratic drug-induced hepatitis. ( 16467335 )
2006
46
Khat--a novel cause of drug-induced hepatitis. ( 16864024 )
2006
47
Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfibrozil in therapy. ( 16645237 )
2006
48
Drug-induced hepatitis with saquinavir/ritonavir + rifampin. ( 15828118 )
2005
49
The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected]. ( 15599214 )
2005
50
Clinical evaluation of drug-induced hepatitis. ( 15982181 )
2005

Variations for Drug-Induced Hepatitis

Expression for Drug-Induced Hepatitis

Search GEO for disease gene expression data for Drug-Induced Hepatitis.

Pathways for Drug-Induced Hepatitis

Pathways related to Drug-Induced Hepatitis according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 CYP2C19 CYP2C9 CYP2D6 CYP2E1 GSTM1 GSTT1
2
Show member pathways
12.93 CYP2C19 CYP2C9 CYP2D6 CYP2E1 GSTM1 GSTT1
3
Show member pathways
11.93 CYP2C19 CYP2C9 CYP2D6 CYP2E1 GSTM1 GSTT1
4
Show member pathways
11.79 CYP2C19 CYP2C9 CYP2E1
5 11.77 CYP2C19 CYP2C9 CYP2D6
6
Show member pathways
11.69 CYP2C19 CYP2C9 CYP2D6 UGT1A3
7
Show member pathways
11.62 CYP2C19 CYP2C9 CYP2D6 CYP2E1
8
Show member pathways
11.55 CYP2D6 CYP2E1 GSTM1 GSTT1 UGT1A3
9 11.51 GSTM1 GSTT1
10
Show member pathways
11.51 CYP2C19 CYP2C9 CYP2D6 CYP2E1
11
Show member pathways
11.46 CYP2E1 UGT1A3
12
Show member pathways
11.41 CYP2C19 CYP2C9 CYP2D6 CYP2E1 UGT1A3
13
Show member pathways
11.37 CYP2C19 CYP2C9
14 11.34 CYP2C19 CYP2C9
15
Show member pathways
11.27 GSTM1 NAT2
16 11.19 CYP2C19 CYP2D6
17 11.18 CYP2C19 CYP2C9 UGT1A3
18 11.16 CYP2C9 CYP2E1
19
Show member pathways
11.14 GSTM1 UGT1A3
20
Show member pathways
11.08 CYP2C9 CYP2E1 NAT2
21 11.06 GSTM1 GSTT1
22 11.05 CYP2C9 CYP2E1 GSTM1 GSTT1
23
Show member pathways
11.02 CYP2C9 CYP2E1
24
Show member pathways
10.94 CYP2C19 CYP2C9 CYP2D6 CYP2E1 UGT1A3
25 10.91 CYP2C9 UGT1A3
26 10.88 CYP2C9 CYP2E1
27 10.71 CYP2D6 UGT1A3
28 10.67 CYP2C9 UGT1A3
29 10.29 CYP2E1 GSTM1

GO Terms for Drug-Induced Hepatitis

Cellular components related to Drug-Induced Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.65 CYP2C19 CYP2C9 CYP2D6 CYP2E1 UGT1A3
2 endoplasmic reticulum membrane GO:0005789 9.55 CYP2C19 CYP2C9 CYP2D6 CYP2E1 UGT1A3
3 intracellular membrane-bounded organelle GO:0043231 9.35 CYP2C19 CYP2C9 CYP2D6 CYP2E1 UGT1A3
4 organelle membrane GO:0031090 8.92 CYP2C19 CYP2C9 CYP2D6 CYP2E1

Biological processes related to Drug-Induced Hepatitis according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.84 CYP2C19 CYP2C9 CYP2D6 CYP2E1
2 steroid metabolic process GO:0008202 9.76 CYP2C19 CYP2C9 CYP2D6 CYP2E1
3 drug metabolic process GO:0017144 9.62 CYP2C19 CYP2C9 CYP2D6 CYP2E1
4 long-chain fatty acid biosynthetic process GO:0042759 9.61 CYP2C9 CYP2D6 CYP2E1
5 epoxygenase P450 pathway GO:0019373 9.58 CYP2C19 CYP2C9 CYP2E1
6 exogenous drug catabolic process GO:0042738 9.56 CYP2C19 CYP2C9 CYP2D6 CYP2E1
7 glutathione metabolic process GO:0006749 9.55 GSTM1 GSTT1
8 heterocycle metabolic process GO:0046483 9.54 CYP2C19 CYP2D6 CYP2E1
9 glutathione derivative biosynthetic process GO:1901687 9.52 GSTM1 GSTT1
10 omega-hydroxylase P450 pathway GO:0097267 9.51 CYP2C19 CYP2C9
11 oxidative demethylation GO:0070989 9.49 CYP2C9 CYP2D6
12 drug catabolic process GO:0042737 9.48 CYP2C9 CYP2D6
13 organic acid metabolic process GO:0006082 9.46 CYP2C19 CYP2C9 CYP2D6 CYP2E1
14 xenobiotic metabolic process GO:0006805 9.35 CYP2C19 CYP2C9 CYP2D6 CYP2E1 NAT2
15 monoterpenoid metabolic process GO:0016098 8.92 CYP2C19 CYP2C9 CYP2D6 CYP2E1

Molecular functions related to Drug-Induced Hepatitis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.73 CYP2C19 CYP2C9 CYP2D6 CYP2E1
2 heme binding GO:0020037 9.71 CYP2C19 CYP2C9 CYP2D6 CYP2E1
3 enzyme binding GO:0019899 9.67 CYP2C19 CYP2E1 GSTM1
4 iron ion binding GO:0005506 9.67 CYP2C19 CYP2C9 CYP2D6 CYP2E1
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.56 CYP2C19 CYP2C9 CYP2D6 CYP2E1
6 drug binding GO:0008144 9.51 CYP2C9 CYP2D6
7 arachidonic acid epoxygenase activity GO:0008392 9.5 CYP2C19 CYP2C9 CYP2E1
8 oxygen binding GO:0019825 9.48 CYP2C19 CYP2E1
9 glutathione transferase activity GO:0004364 9.46 GSTM1 GSTT1
10 monooxygenase activity GO:0004497 9.46 CYP2C19 CYP2C9 CYP2D6 CYP2E1
11 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.26 CYP2C19 CYP2C9 CYP2D6 CYP2E1
12 steroid hydroxylase activity GO:0008395 8.92 CYP2C19 CYP2C9 CYP2D6 CYP2E1

Sources for Drug-Induced Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....